News

Raised cancer risk remains for years after HRT stopped

07-Mar-08

Women who have stopped taking oestrogen plus progesterone HRT could still be at an increased risk of developing cancer three years later, US research suggests.

In 2002, the Women's Health Initiative (WHI) study was terminated early after oestrogen plus progesterone HRT was found to be linked to a 26 per cent increased risk of breast cancer and a 29 per cent higher risk of heart attack.

Subsequently, women have been advised to take HRT for as short a time as possible. But follow-up data from the WHI suggests that the increased cancer risk remains after stopping HRT.

The latest data comes from follow-up of 15,730 postmenopausal women, aged 50-79, who had participated in the WHI study. Half the women had been taking oestrogen plus progesterone HRT, but stopped the treatment in 2002 when the WHI study was abandoned. The rest of the women had taken placebo.

Follow-up from July 2002 until March 2005 revealed that 281 women who had received HRT went on to develop cancer, compared with 218 who had not received HRT.

Overall, the combined risk of suffering heart disease, stroke, hip fracture or cancer was 12 per cent higher in the HRT group than the placebo group.

Researchers from the University of North Carolina hope the findings can help calculate the optional use of HRT.

Dr Kat Arney, Cancer Research UK's senior information officer, said: 'This significant study adds to the evidence that women should only take HRT specifically to treat symptoms of the menopause, and for as short a time as possible.

'Women who are taking HRT and are concerned about their risk of cancer should speak to their doctor.'

sanjay.tanday@haymarket.com

JAMA 2008; 299: 1,036-45

Comment below and tell us what you think 

Comments

Only registered users may comment. Log in now or register for a free account.

Login to comment


forgotten your password?

Healthcare Republic Forums

 

Registrar

nMRCGP exam update - Evidence for aspirin use

Contributed by Dr Louise Newson, a GP in the West Midlands. Read more

RCGP curriculum - Introducing the GP curriculum

Dr Ben Riley and Dr Jayne Haynes explain what the curriculum is and why it is necessary. Read more

Alcohol problems in young people

Greater awareness of drinking problems is needed, say Professor Eileen Kaner and Ruth McGovern. Read more

Show all articles

 

Latest Clinical Articles

Altitude-related illness

Contributed by Dr Matthew Litchfield, GP, Nottingham and Dr James Milledge, retired consultant respi... Read more

Clinical Review - Subfertility in women

Contributed by Mr David Walker, consultant obstetrician and gynaecologist at the Royal United Hospit... Read more

Stable angina pectoris

Contributed by Dr Unni Krishnan, clinical research fellow in cardiology at the Glenfield Hospital, L... Read more

Show all clinical articles

MIMS Product News

Relistor

New drug - Relistor

Wyeth has launched Relistor (methylnaltrexone bromide) for the treatment of opioid-induced constipat... Read more

Thalidomide available in the UK

Thalidomide, under the name of Thalidomide Pharmion is now commercially available in the UK. Read more

MMR catch-up programme

The DoH has written to healthcare professionals to call for urgent action to help reduce the risk of... Read more

Jobs

 

Job of the Week